STOCK TITAN

[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) director Chris Cleary received new equity compensation grants on June 24, 2025. The awards consist of:

  • 12,422 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 22,577 shares
  • 36,797 Stock Options with an exercise price of $3.22 per share, expiring June 24, 2035

Both the RSUs and stock options will vest in a single installment at the earlier of: (1) one-year anniversary of grant date or (2) the 2026 Annual Meeting of Stockholders, subject to continued service. This Form 4 filing was submitted by Andrew Taylor as attorney-in-fact on June 26, 2025, reflecting standard director compensation arrangements.

Chris Cleary, direttore di Orchestra BioMed Holdings (OBIO), ha ricevuto nuove concessioni di compensi azionari il 24 giugno 2025. Gli incentivi comprendono:

  • 12.422 Unità di Azioni Vincolate (RSU) con prezzo di esercizio pari a 0$, portando la proprietà diretta totale a 22.577 azioni
  • 36.797 Opzioni Azionarie con prezzo di esercizio di 3,22$ per azione, con scadenza il 24 giugno 2035

Sia le RSU che le opzioni azionarie matureranno in un'unica soluzione alla prima delle seguenti date: (1) anniversario di un anno dalla data di concessione oppure (2) Assemblea Annuale degli Azionisti del 2026, subordinatamente alla continuazione del servizio. Questa comunicazione Form 4 è stata presentata da Andrew Taylor come procuratore il 26 giugno 2025, riflettendo le consuete modalità di compenso per i direttori.

Chris Cleary, director de Orchestra BioMed Holdings (OBIO), recibió nuevas concesiones de compensación en acciones el 24 de junio de 2025. Las adjudicaciones consisten en:

  • 12,422 Unidades de Acciones Restringidas (RSU) con precio de ejercicio de $0, aumentando la propiedad directa total a 22,577 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22 por acción, que expiran el 24 de junio de 2035

Tanto las RSU como las opciones sobre acciones se consolidarán en un solo pago en la fecha que ocurra primero entre: (1) el aniversario de un año desde la fecha de concesión o (2) la Reunión Anual de Accionistas de 2026, sujeto a la continuación del servicio. Esta presentación del Formulario 4 fue realizada por Andrew Taylor como apoderado el 26 de junio de 2025, reflejando los arreglos estándar de compensación para directores.

Orchestra BioMed Holdings(OBIO)의 이사 크리스 클리어리가 2025년 6월 24일에 새로운 주식 보상 권한을 받았습니다. 수여 내역은 다음과 같습니다:

  • 12,422 제한 주식 단위(RSUs) 행사가격 $0, 총 직접 보유 주식 수는 22,577주로 증가
  • 36,797 주식 옵션 주당 행사가격 $3.22, 만료일은 2035년 6월 24일

RSU와 주식 옵션은 계속 근무 조건하에 (1) 수여일로부터 1년 기념일 또는 (2) 2026년 주주총회 중 빠른 시점에 한 번에 모두 취득됩니다. 이 Form 4 제출은 2025년 6월 26일 법정대리인인 앤드류 테일러가 제출했으며, 표준 이사 보상 조건을 반영합니다.

Chris Cleary, administrateur d'Orchestra BioMed Holdings (OBIO), a reçu de nouvelles attributions de rémunération en actions le 24 juin 2025. Les attributions se composent de :

  • 12 422 unités d'actions restreintes (RSU) avec un prix d'exercice de 0 $, portant la propriété directe totale à 22 577 actions
  • 36 797 options d'achat d'actions avec un prix d'exercice de 3,22 $ par action, expirant le 24 juin 2035

Les RSU et les options d'achat d'actions seront acquises en une seule fois à la date la plus proche entre : (1) le premier anniversaire de la date d'attribution ou (2) l'assemblée générale annuelle des actionnaires de 2026, sous réserve de la poursuite du service. Ce dépôt du formulaire 4 a été soumis par Andrew Taylor en tant que mandataire le 26 juin 2025, reflétant les modalités habituelles de rémunération des administrateurs.

Chris Cleary, Direktor von Orchestra BioMed Holdings (OBIO), erhielt am 24. Juni 2025 neue Aktienvergütungen. Die Zuteilungen bestehen aus:

  • 12.422 Restricted Stock Units (RSUs) mit einem Ausübungspreis von 0 $, wodurch der Gesamtbesitz auf 22.577 Aktien steigt
  • 36.797 Aktienoptionen mit einem Ausübungspreis von 3,22 $ pro Aktie, gültig bis zum 24. Juni 2035

Sowohl die RSUs als auch die Aktienoptionen werden in einer einzigen Tranche zum früheren Zeitpunkt von (1) dem einjährigen Jubiläum des Zuteilungsdatums oder (2) der Hauptversammlung 2026 fällig, vorbehaltlich fortgesetzter Dienstzeit. Diese Form 4 Einreichung wurde am 26. Juni 2025 von Andrew Taylor als Bevollmächtigter eingereicht und spiegelt die üblichen Vergütungsregelungen für Direktoren wider.

Positive
  • None.
Negative
  • None.

Chris Cleary, direttore di Orchestra BioMed Holdings (OBIO), ha ricevuto nuove concessioni di compensi azionari il 24 giugno 2025. Gli incentivi comprendono:

  • 12.422 Unità di Azioni Vincolate (RSU) con prezzo di esercizio pari a 0$, portando la proprietà diretta totale a 22.577 azioni
  • 36.797 Opzioni Azionarie con prezzo di esercizio di 3,22$ per azione, con scadenza il 24 giugno 2035

Sia le RSU che le opzioni azionarie matureranno in un'unica soluzione alla prima delle seguenti date: (1) anniversario di un anno dalla data di concessione oppure (2) Assemblea Annuale degli Azionisti del 2026, subordinatamente alla continuazione del servizio. Questa comunicazione Form 4 è stata presentata da Andrew Taylor come procuratore il 26 giugno 2025, riflettendo le consuete modalità di compenso per i direttori.

Chris Cleary, director de Orchestra BioMed Holdings (OBIO), recibió nuevas concesiones de compensación en acciones el 24 de junio de 2025. Las adjudicaciones consisten en:

  • 12,422 Unidades de Acciones Restringidas (RSU) con precio de ejercicio de $0, aumentando la propiedad directa total a 22,577 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22 por acción, que expiran el 24 de junio de 2035

Tanto las RSU como las opciones sobre acciones se consolidarán en un solo pago en la fecha que ocurra primero entre: (1) el aniversario de un año desde la fecha de concesión o (2) la Reunión Anual de Accionistas de 2026, sujeto a la continuación del servicio. Esta presentación del Formulario 4 fue realizada por Andrew Taylor como apoderado el 26 de junio de 2025, reflejando los arreglos estándar de compensación para directores.

Orchestra BioMed Holdings(OBIO)의 이사 크리스 클리어리가 2025년 6월 24일에 새로운 주식 보상 권한을 받았습니다. 수여 내역은 다음과 같습니다:

  • 12,422 제한 주식 단위(RSUs) 행사가격 $0, 총 직접 보유 주식 수는 22,577주로 증가
  • 36,797 주식 옵션 주당 행사가격 $3.22, 만료일은 2035년 6월 24일

RSU와 주식 옵션은 계속 근무 조건하에 (1) 수여일로부터 1년 기념일 또는 (2) 2026년 주주총회 중 빠른 시점에 한 번에 모두 취득됩니다. 이 Form 4 제출은 2025년 6월 26일 법정대리인인 앤드류 테일러가 제출했으며, 표준 이사 보상 조건을 반영합니다.

Chris Cleary, administrateur d'Orchestra BioMed Holdings (OBIO), a reçu de nouvelles attributions de rémunération en actions le 24 juin 2025. Les attributions se composent de :

  • 12 422 unités d'actions restreintes (RSU) avec un prix d'exercice de 0 $, portant la propriété directe totale à 22 577 actions
  • 36 797 options d'achat d'actions avec un prix d'exercice de 3,22 $ par action, expirant le 24 juin 2035

Les RSU et les options d'achat d'actions seront acquises en une seule fois à la date la plus proche entre : (1) le premier anniversaire de la date d'attribution ou (2) l'assemblée générale annuelle des actionnaires de 2026, sous réserve de la poursuite du service. Ce dépôt du formulaire 4 a été soumis par Andrew Taylor en tant que mandataire le 26 juin 2025, reflétant les modalités habituelles de rémunération des administrateurs.

Chris Cleary, Direktor von Orchestra BioMed Holdings (OBIO), erhielt am 24. Juni 2025 neue Aktienvergütungen. Die Zuteilungen bestehen aus:

  • 12.422 Restricted Stock Units (RSUs) mit einem Ausübungspreis von 0 $, wodurch der Gesamtbesitz auf 22.577 Aktien steigt
  • 36.797 Aktienoptionen mit einem Ausübungspreis von 3,22 $ pro Aktie, gültig bis zum 24. Juni 2035

Sowohl die RSUs als auch die Aktienoptionen werden in einer einzigen Tranche zum früheren Zeitpunkt von (1) dem einjährigen Jubiläum des Zuteilungsdatums oder (2) der Hauptversammlung 2026 fällig, vorbehaltlich fortgesetzter Dienstzeit. Diese Form 4 Einreichung wurde am 26. Juni 2025 von Andrew Taylor als Bevollmächtigter eingereicht und spiegelt die üblichen Vergütungsregelungen für Direktoren wider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cleary Chris

(Last) (First) (Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE

(Street)
NEW HOPE PA 18938

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share ("Common Stock") 06/24/2025 A 12,422(1) A $0 22,577 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.22 06/24/2025 A 36,797 (2) 06/24/2035 Common Stock 36,797 $0 36,797 D
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
2. The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
/s/ Andrew Taylor, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did OBIO director Chris Cleary receive on June 24, 2025?

Chris Cleary received 36,797 stock options with an exercise price of $3.22 per share. These options will vest in one installment on either the one-year anniversary of the grant date (June 24, 2026) or the date of OBIO's 2026 Annual Meeting of Stockholders, whichever comes first.

How many restricted stock units (RSUs) were granted to Chris Cleary at OBIO?

Chris Cleary was granted 12,422 restricted stock units (RSUs) on June 24, 2025. Each RSU represents one share of common stock and will vest in one installment on either June 24, 2026 or the date of OBIO's 2026 Annual Meeting of Stockholders, whichever occurs first.

When do Chris Cleary's OBIO stock options expire?

The stock options granted to Chris Cleary expire on June 24, 2035, which is 10 years from the grant date of June 24, 2025.

How many shares of OBIO common stock does Chris Cleary own directly after the June 24, 2025 transactions?

Following the reported transactions, Chris Cleary directly owns 22,577 shares of OBIO common stock, plus 12,422 unvested RSUs and 36,797 unvested stock options.
Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

OBIO Latest News

OBIO Latest SEC Filings

OBIO Stock Data

115.32M
25.43M
21.82%
55.5%
1.39%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
NEW HOPE